CS

Carol Suh

Partner at ARCH Venture Partners, Co-founder of Neumora

San Francisco Bay Area

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $50,000.00

  • Max Investment:

    $150,000,000.00

  • Target Investment:

    $25,000,000.00

Skills

Stem Cells
Genetics
Biochemistry
Cell
Research
Molecular Biology
Data Analysis
Cell Culture
Cell Biology
Pharmacology
PCR
Cancer
Life Sciences

Education

Investments

HI-Bio

Series A

Total Funding: $220M

Orbital Therapeutics

Seed

Total Funding: $270M

Work Experience

ARCH Venture Partners

2018

  • Partner

    2021

    Board Member: Orbital Therapeutics, Human Immunology Biosciences (acquired) Board Observer: Kisbee Therapeutics (2021-Present), Remix Therapeutics (2021-Present), Resonance Medicine (2021-2023), Sesh Therapy (2021-2023), Locana Bio (2020-2024), CERo Therapeutics (2020-2022), Metacrine (2019-2020),

  • Principal

    2019 - 2021

  • Senior Associate

    2018 - 2019

  • Consultant/Intern

    2018 - 2018

Neumora

2019

  • Co-Founder and Chief Operating Officer

    2023

  • Co-Founder and SVP, Strategy

    2022 - 2023

  • Co-founder and VP, Business Development

    2019 - 2021

Orbital Therapeutics

2022

  • Co-founder, Board Member

    2022

HIBio

2021

  • Board Member

    2021

Metrodora Institute

2021

  • Board Member of Metrodora Foundation

    2021

Boundless Bio

2019 - 2019

  • Associate Director of Corporate Development

    2019 - 2019

    ARCH Venture Partners company build

Magenta Therapeutics

2016 - 2017

  • Business Development and Corporate Strategy Associate; Launch Fellow

    2016 - 2017

    Business Development and Corporate Strategy Associate (Jun 2017-Sept 2017) Launch Fellow (May 2016-Aug 2016): Helped prepare Magenta Therapeutics for launch and $48.5M Series A, working with Third Rock Ventures and Atlas Venture.

Trinity Partners

2015 - 2016

  • Senior Associate Consultant

    2015 - 2016

    Senior Associate Consultant (2016) Associate Consultant (2015)

GlaxoSmithKline

2014 - 2014

  • R&D Strategy; Innovation Fellow

    2014 - 2014

    The Regenerative Medicine Discovery Performance Unit built a portfolio of innovative stem cell and regenerative medicines through in-house R&D, strategic alliances, and in-licensing opportunities.